IL5 and Increased total eosinophil count: However, the use of mepolizumab, an anti-IL-5 antibody, in the first clinical trial did not result in a decrease in SCORAD indices and did not significantly affect the pruritus score and the TARC severity marker compared to the control, despite a reduction in eosinophilia [43].